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Abstract 
Objectives: To report longitudinal outcomes of a population based cohort of patients 
diagnosed with bilateral small renal masses from a period of over 11 years.    
Patients and Methods: Consecutive patients diagnosed with bilateral small renal 
masses (synchronous or metachronous) of a defined geographical area were recorded in 
a large database (TUCAN database) between January 2005 and December 2016.  
Patients had a unique identifier number and followed during this period using an agreed 
upon protocol.  Clinicopathological characteristics and outcomes of bilateral small renal 
masses on active surveillance were analysed and compared to propensity score matched 
sporadic unilateral small renal masses.  Data were analysed for renal mass growth rate, 
rate of intervention and development of metastatic disease and patient survival.    
Results: A total of 1060 patients were diagnosed with renal cancer, of which bilateral 
small renal masses accounted for 70 (6.6%) cases.  Synchronous SRMs were observed 
in 63 patients, whereas metachronous lesions were found in seven patients during the 
study period.  Metachronous lesion mean time to appearance was 62 ± 41 months 
(range, 9 to 149 months). While most cases were sporadic, four were found to be 
hereditary.  Growth rate of bilateral small renal masses did not differ from that of 
unilateral sporadic small renal masses.  Similarly, there were no differences between 
the groups for rate of interventions and survival.     
 
Conclusion: Progression, rate of metastases and survival for patients diagnosed with 
bilateral small renal masses is similar to those diagnosed with unilateral disease.   
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1. Introduction 
There is an extensive body of literature reporting on the topic of unilateral renal cancers.  
However, there is a limited number of reports that have studied outcomes of patients 
diagnosed with bilateral renal cell carcinomas [1-3]. The natural histories of metachronous 
and synchronous small renal masses (less than 4 cm) are incompletely understood. Most 
reports on these topics consist of a single or small case series discussing outcomes relating to 
partial nephrectomy [4, 5].  As such, there has been a rise in the prevalence of bilateral renal 
cancers due to a number of contributing factors including overall growth of renal cancer 
incidence rates, early detection due to cross sectional imaging, increased life expectancy 
and longer follow-up periods of cancer survivors [6, 7].  These and other factors have 
resulted in an increasing number of people at risk for developing metachronous or 
synchronous bilateral primary renal cancer.   
Optimal clinical management of patients presenting with cancers affecting both renal units 
is challenging.  Preservation of renal function, optimal oncological control and providing 
long-term cancer recurrence free survival are the main objectives of management [8-11]. 
However, the decision making process during this care can be confounded by effects of age, 
co-morbid conditions and preferences of patients.  Further complicating patient care 
strategies, the rate of progression and interventions for incidentally detected small renal 
masses (SRMs) found in contralateral renal units during initial or follow-up imaging of 
treated renal cancers remains poorly understood.   While there have been reports out of 
Norway and Sweden that have analysed large patient datasets [12], crucial information such 
as histology, grade of cancer, type of intervention including surgical management and long-
term follow-up renal function is lacking.  Finally, recent data suggests there is a 17 fold 
increased risk for developing contralateral renal tumours in certain patients under 40 years 
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of age.  How multifocal disease with an underlying genetic predisposition should be 
managed remains open to question.   Therefore, to understand and answer some of these 
questions, we analysed a large database of renal cancer patients in a well-defined 
geographical area with a population of more than 400,000 provided by a single National 
Health Services (NHS) Health board in Scotland.   
The two primary aims of this study were, 1) identify the incidence of synchronous and 
metachronous small renal masses in a large population, and 2) provide details on long-term 
outcomes of patients diagnosed with these lesions.   
 
 
 
 
 
 
 
 
 
 
 
4
2. Patients and methods 
2.1 Study Cohort 
The study cohort was drawn from a well-defined geographical area over a defined time 
period. The population of the area was stable with less than 1% migration and more than 
98% registered with NHS through a unique identifier called CHI number (Community Health 
Index-CHI). For various indications, 160,820 abdominal imaging tests (CT, MRI, US) were 
carried out in a population of 118,600 as reported previously [13]. Since 2005, all new 
primary renal cancers in the region were managed within a single Health Board and each 
case was recorded at local multidisciplinary meetings run by a local Urological Cancers 
Network (TUCAN).  Any patient with renal mass (solid on cystic) on imaging is referred to a 
single point (department of urology) in the region and none of these are managed in 
primary care.  A MS word file was generated for each patient and stored in computer on a 
shared password protected computer drive following review of radiology and 
histopathology.  The word file contained unique identifier number (CHI), demographic 
details, type of presentation, stage, histology, grade, radiological finding and final consensus 
decision of the multidisciplinary team.  Our previous reports have validated the data quality 
of this process including record linkage methodology through a common identifier (CHI 
number) using a deterministic record linkage strategy [13-15]. Figure 1 summarises the 
study cohort, flow and systems used for record-linkage.  We Identified 1600 patients 
(treated and untreated) with a primary renal cancer during the study period. Some of these 
had no histological diagnosis but imaging were convincing of RCC. TUCAN database captures 
all patients including those with radiographic masses with possibility of RCC.  Out of the 
total sample, there were 70 patients with synchronous (presenting simultaneously at the 
same time) or metachronous (developing more than 6 months of initial treatment for 
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unilateral renal lesion) small renal masses. We excluded patients diagnosed with large 
bilateral renal cancers (>4 cm) with or without metastatic disease.  Patients were also 
excluded if they demonstrated benign masses confirmed via histopathology analysis 
following biopsies.   All aspects of this study were approved by the Institutional Review 
Board (Caldicott/CSAppGN021211; Caldicott/IGTCAL2973).    
Collected data included radiological details at diagnosis and follow-up imaging.  
Demographic characteristics, number and type of interventions, complications and follow-up 
outcomes were analysed.  A primary interest of this study was to assess the growth rate of 
those masses on active surveillance as we have recently published on a larger cohort focusing 
on active surveillance [15]. 
All patients suspected to have small renal masses who were referred to the department were 
given detailed clinical evaluations, abdominopelvic CT scans with a defined protocol chest 
X-ray and discussions in multidisciplinary meetings.  Each patient was assigned a defined 
management plan, which included surgical approaches and active surveillance.  Surgical 
approaches/interventions were: radical nephrectomy, partial nephrectomy (open) and 
radiofrequency ablation.  For those opting for active surveillance, follow-up imaging 
included CT scanning at 6 month intervals for three years and yearly thereafter.   A group of 
patients diagnosed with bilateral small renal masses were compared with those diagnosed 
with unilateral disease using propensity score matching for variables known to influence 
growth such as size, location etc. Progression was defined as any increase in size on follow-
up or change in tumour characteristic on follow-up imaging as described previously [13, 15]. 
 
For the active surveillance group, bilateral non-hereditary small renal masses were 
compared to a control group of patients diagnosed with unilateral sporadic lesions. Control 
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group of patients were with unilateral small renal masses on active surveillance during the 
same period.  Matching was accomplished using propensity score matching using SPSS v21 
software programme and variables such as age, sex, size of SRMs, location, duration, co-
morbidities etc. Progression, metastases, need for intervention and survival analyses were 
carried out.  
 
Bilateral renal masses in this study were managed using following strategies: 1) for those 
with identified genetic abnormalities, a close radiological surveillance protocol was offered, 
which included minimally invasive interventions for larger masses (>3 cm) at presentation or 
whenever they grow to this size. All patients were managed by a multidisciplinary team 
because there are other sites where abnormalities can develop such as central nervous 
system, other organs etc.  Genetic counselling was also made available through a dedicated 
service;  2) all patients with SRMs <3 cm were offered active surveillance and interventions 
were contemplated in those with growing masses or those reluctant to enter active 
surveillance (AS).   Nephron sparing surgery was carried out in most cases.  This was 
achieved using a two-stage procedure (one side operating at one time and contralateral on a 
second setting) in most patients; and 3) image guided biopsies were offered to all patients 
demonstrating a tumour size more than 2 cm.  
 
Following surgical or minimally invasive ablations, abdominal CT or MRI and chest X-ray 
were carried out every 3–6 months, and then annually during the first 5 years and every 2 
years thereafter for life long [14].  Recurrence, if noted, was re-discussed in multidisciplinary 
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meetings and appropriate plans were made.  Recurrence free and overall survival was 
calculated for unilateral and bilateral renal masses (non-hereditary). 
 
2.2 Statistical Analysis 
Bilateral small renal masses diagnosed within 6 months of the first primary visit were 
categorized as synchronous, whereas the remaining cancers were categorized as 
metachronous.  Patient outcomes for those with bilateral renal masses were compared with 
those with unilateral masses.  Associations between clinicopathological characteristics and 
follow-up outcomes were analysed using univariate and multivariate cox proportional 
hazards regression models. The goal of the main analysis was to determine outcome of non-
hereditary bilateral SRMs on active surveillance compared with the unilateral SRMs. To 
assess the adjusted relation we performed propensity score matching with dependable 
variable being progression of SRMs.  We included all variables which could potentially be 
confounding based on prior work and /or clinical reasoning. Matching consisted of three 
steps:  a) propensity scores were developed using covariates which predicted progression of 
SRMs ; and a forward stepwise procedure was used to explore whether baseline 
characteristics of SRMs such as age, sex, size, duration, presentation, co-morbidities, were 
also associated with progression at the p<0.10 level. b)  This logistic regression model was 
used to calculate propensity scores representing the estimated probability of progression 
contingent on each baseline characteristics.  Bilateral SRMs were matched to the unilateral 
SRMs with the closest propensity score on a ratio of 1:1 using a nearest neighbour greedy 
algorithm.  c) Various checks were performed to that model was adequate.  These included 
means and variances of covariates after matching, standardised mean differences between 
bilateral and unilateral SRMs.  A matching bias was kept to ≤5% to ensure an adequate 
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model.  Recurrence free, cancer specific and overall survival was assessed using Kaplan–
Meier analysis using the log-rank test. Statistical significance was determined using an alpha 
level of 0.05. Statistical analyses were carried out using SSPS (version 21). 
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 3.0 Results  
Table 1 shows basic demographic characteristics of the cohort.  Most patients 
demonstrated sporadic synchronous lesions and were predominantly present in males. 
More than half of the patients (37/70; 52.8%) had surgical excision (radical nephrectomy 
and nephron sparing surgery).  Histological testing showed clear cell carcinoma in most 
patients.  Excised tumours were of low grade in most patients.  33 patients opted for active 
surveillance (AS) with a mean follow-up of more than 6 years.  Figure 2 shows progression 
rate of bilateral small renal masses on AS in comparison to unilateral small renal masses.  
There were no statistically significant differences between the two groups. Increases in size 
of bilateral synchronous lesions were 0.2 cm/year compared to 0.25 mm/year for unilateral 
small renal masses. Patients with familial disease (n=4) were managed using minimally 
invasive treatment options (radiofrequency ablation).  Larger lesions (more than 3 cm) were 
targeted for ablation (radiofrequency ablation in most) on follow-up.  None of the patients 
developed renal failure or metastatic disease.   There were seven patients with 
metachronous lesions.  Mean time for appearance of metachronous lesion was 62 ± 41 
months (range, 9 to 149 months).     
 In patients where a surgical approach was contemplated, the nephron sparing approach 
(partial nephrectomy) was the main surgical technique utilized.  All partial excisions were 
carried out sequentially with mean duration of 7.0 ± 4.5 weeks between procedures.  Seven 
patients had laparoscopic radical nephrectomy due to central location of tumours or where 
it was thought that partial excision will be risky with potential of higher morbidity. None of 
the patients undergoing bilateral partial nephrectomy required dialysis or renal replacement 
therapy.   
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Thirty three patients with bilateral small renal masses on AS were compared with 30 
patients with unilateral small renal masses.  With a mean follow-up of more than 6 years, 
there were no differences in the rate of intervention, growth rate and development of 
metastatic disease (Figure 3, supplementary).     
In four patients with non-sporadic disease (hereditary disorders) and multiple bilateral SRMs 
(Figure 4-supplementary), interventions were tailored to the progression of disease.  
Radiofrequency ablation was offered to patients demonstrating larger masses on follow-up, 
whereas patients demonstrating small lesions (<3 cm) were followed-up using MRI/CT scan 
at regular intervals.  All four cases are asymptomatic, preserved renal function and no 
evidence of metastatic disease (Table 2).   
Image guided renal biopsy testing was used to confirm histopathology in 12 patients (18 
renal units) in the AS group.  Most of these showed the presence of renal cell carcinoma.   
There were four patients, where biopsy confirmed benign oncocytoma and further 
interventions were avoided and discharged from secondary care (not part of this study).  
Figure 5 (supplementary) shows benign oncocytoma confirmed on histopathology in an 80 
year old lady with previous contralateral nephrectomy for centrally located kidney tumour.   
There were no differences in metastases free, disease specific or overall survival between 
those with unilateral small renal masses in comparison to bilateral disease (Figure 6, 
supplementary).   
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4.0 Discussion 
The present longitudinal population based study assessed the outcomes of bilateral small 
renal masses and found no marked differences between non-hereditary bilateral 
synchronous and sporadic propensity matched unilateral renal masses in terms of 
progression, development of metastatic disease and need for interventional procedures 
including surgery. When patients diagnosed with bilateral synchronous SRMs opting for 
active surveillance were compared with those diagnosed with unilateral disease, 
progression rate and development of distant metastases did not differ between the two 
groups. 
Managing bilateral small renal masses with underlying hereditary abnormalities is a 
challenging issue.  The approach of managing hereditary lesions should be aimed at 
maintaining quality of life and keeping morbidity as low as possible.  Active surveillance 
along with minimally invasive interventions as described in a small number of cases in this 
study should preserve renal function and provide metastases free survival.  Alternate option 
of aggressive approach of bilateral radical nephrectomy and renal transplantation should be 
reserved for locally advanced and larger masses.   Our approach (active surveillance with 
minimally invasive intervention on growth) of managing is similar to described by others 
[16-18] and is based on the assumption (backed by reports in the literature) that tumour 
size less than 3 cm show low rate of metastases and progression. Small renal masses with 
hereditary genetic abnormalities seen in our series were very aggressive and some 
demonstrated interval growth of more than 3 cm.  They required on average four 
procedures per patient over a mean period of 46 months of follow-up.  All these procedures 
were day case and patients had no complications.  Further studies in larger cohort of 
patients are required to confirm the proposed benefits of this approach. 
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Non-hereditary bilateral synchronous SRMs showed no striking differences to unilateral 
SRMs in terms of progression and development of metastatic disease when they opted for 
active surveillance.  This is noteworthy and consistent with findings of Blute et al. [19]. 
Observations in this study suggest that despite bilateralism, SRMs behaviour in a particular 
size range (<4 cm) remains the same.  In our experience, most of metastases develop within 
first two years of follow-up and some of these may be missed subtle disease in distant 
organs at the time of first detection [20]. In contrast to hereditary disease, where growth is 
fast and multiple interventions are anticipated, non-hereditary disease with bilateral 
synchronous renal cell carcinoma can be managed by a single nephron-sparing surgery with 
acceptable morbidity. 
The rate of metachrnous lesion was low compared to reports in the literature [12, 19, 21]. This 
can be explained by the fact that present study cohort restricted study inclusion to small 
renal masses as opposed to including renal masses of all sizes.  Furthermore, we did not 
include patients with hereditary or familial predisposition to development of contralateral 
disease.  Small size of the present study may be another contributing factor. Metachronous 
lesion, however did show up even after five years of treatment of localised small renal 
masses, highlighting the importance of long-term follow-up of treated small renal masses.  
This again is similar to evidence from a previous report [22].  An interesting hypothesis and 
perhaps ongoing debate that metachronous lesion may represent metastatic disease remains to 
settled.  There is need for molecular genetic data to confirm or refute this and in the absence 
of further scientific proof, this cannot be confirmed.  Most patients in metachronous disease 
in the present study (6/7) had similar histology (clear cell carcinoma) to the previous 
contralateral tumours. In one remaining case, there was papillary cell carcinoma in the 
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metachronous lesion.  In contrast to Boorjian et al [23], most of bilateral synchronous 
tumours were clear cell renal cell carcinoma in non-hereditary synchronous lesions.   
 
Surgical management of bilateral small renal masses may require a different approach in 
comparison to literature described for larger bilateral masses.  Nephron sparing surgery 
remains the mainstay of management as carried out in the present study.  Radical 
nephrectomy, less common approach is only reserved for technically difficult and centrally 
located lesions.  However, options of minimally invasive interventions (radiofrequency 
ablation/cryo) should be considered as fundamental principle of surgical approach in these 
cases remains nephron sparing and preservation of renal function without compromising 
oncological outcomes.  Whether surgery should be carried out in one-stage or in two stage 
depends on expertise and complexity of the cases.  Careful planning and discussion with 
patient is important.  The essential principles are: eradication of cancer, preservation of renal 
function and avoidance of dialysis and minimizing morbidity.  Procedure should be staged in 
patients where there is high risk of acute kidney injury and prolonged hospitalisation.  Renal 
nephrometry score should be consider as a guide to assess complexity of the lesions as 
postoperative complications and morbidity can be predicted through these score [24, 25]. As 
described above, patients with hereditary small renal masses, should have a combination of 
AS and judicious utilization of minimally invasive treatment options.   
In a subset of patients with synchronous bilateral SRMs on active surveillance, image guided 
biopsies were performed. In smaller renal masses less than 2m, no histological confirmation 
was available in the present cohort.  This is a limitation of the study.  Besides histological 
confirmation, biopsy may provide opportunity for molecular profiling of the SRMs and better 
risk stratification of therapeutic options and follow-up.  Small size and single institutional 
design are the other limitations of the study.  Nevertheless, data in the present cohort provides 
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several insights into managements of hereditary and non-hereditary bilateral small renal 
masses including role of active surveillance.  
 
 
Conclusions:   Progression, rate of metastases and survival of bilateral small renal masses is 
similar to unilateral disease and active surveillance is a safe option in these cases.  Hereditary 
bilateral small renal masses have different growth trajectory and should be considered 
separate entity and managed using active surveillance and minimally invasive ablative 
procedures.  
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Legends for Figures and Tables 
 
Figure 1:  shows flow of cohort and record linkage with databases to update 
information including follow-up. 
Figure 2:  Shows use of image guided biopsies usage in bilateral (non-hereditary) and 
unilateral small renal masses  
Figure 3-supplementary:  shows outcomes of small renal masses (Bilateral vs. 
unilateral) on follow-up. 
Figure 4-supplementary: Multiple bilateral renal masses in a patient with VHL 
hereditary disease. Larger lesions were targeted using minimally invasive ablative 
technique.  
Figure 5-supplementary: Image guided biopsy confirmed oncocytoma as seen on 
MRI in an eighty year old lady with history of previous laparoscopic radical 
nephrectomy for contralateral small renal mass.  
Figure 6-supplementary:  Metastases free survival in unilateral vs. bilateral (non-
hereditary) small renal masses 
 
Table 1: Demographic characteristics of the cohort. 
Tale 2:  Hereditary bilateral small renal masses- follow-up outcomes. 
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